Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBTX advanced for three days, in 188 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
NBTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 23 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.498). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The RSI Indicator for ONCO moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +21.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCO advanced for three days, in 142 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONCO as a result. In 76 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ONCO turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 33 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ONCO moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ONCO crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ONCO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONCO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.260) is normal, around the industry mean (3.498). P/E Ratio (0.009) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.598) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NBTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 61 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 42 | |
P/E GROWTH RATING 1..100 | 27 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| NBTX | ONCO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 81% | 8 days ago 83% |
| Declines ODDS (%) | 10 days ago 82% | 2 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 76% | 7 days ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBTX’s FA Score shows that 2 FA rating(s) are green while ONCO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBTX’s TA Score shows that 4 TA indicator(s) are bullish while ONCO’s TA Score has 3 bullish TA indicator(s).
NBTX (@Biotechnology) experienced а +15.09% price change this week, while ONCO (@Biotechnology) price change was -42.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
NBTX is expected to report earnings on Nov 17, 2026.
ONCO is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, NBTX has been loosely correlated with SLDB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NBTX jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
|---|---|---|---|---|
| NBTX | 100% | +0.24% | ||
| SLDB - NBTX | 35% Loosely correlated | +6.00% | ||
| FDMT - NBTX | 35% Loosely correlated | +4.25% | ||
| ASMB - NBTX | 33% Loosely correlated | +4.78% | ||
| CLLS - NBTX | 33% Loosely correlated | +24.32% | ||
| NAMS - NBTX | 32% Poorly correlated | +8.03% | ||
More | ||||
A.I.dvisor indicates that over the last year, ONCO has been loosely correlated with PCSA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ONCO jumps, then PCSA could also see price increases.
| Ticker / NAME | Correlation To ONCO | 1D Price Change % | ||
|---|---|---|---|---|
| ONCO | 100% | +8.36% | ||
| PCSA - ONCO | 35% Loosely correlated | N/A | ||
| ZURA - ONCO | 33% Loosely correlated | +1.78% | ||
| ABEO - ONCO | 29% Poorly correlated | -6.31% | ||
| NIKI - ONCO | 28% Poorly correlated | -2.48% | ||
| NBTX - ONCO | 25% Poorly correlated | +0.24% | ||
More | ||||